LifeStance Health Group (LFST) to Release Earnings on Wednesday

LifeStance Health Group (NASDAQ:LFST) will likely be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.0539 per share and revenue of $378.5140 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:30 AM ET.

LifeStance Health Group Stock Down 0.6%

NASDAQ LFST opened at $7.15 on Monday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The company has a fifty day moving average of $7.11 and a two-hundred day moving average of $6.13. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of -238.33 and a beta of 1.12. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Barclays began coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price for the company. BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective for the company. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. Finally, UBS Group boosted their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Insider Buying and Selling

In related news, insider Ann Varanakis sold 50,000 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the transaction, the insider owned 315,610 shares of the company’s stock, valued at $2,177,709. This represents a 13.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the transaction, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 270,086 shares of company stock worth $1,891,264. Corporate insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Several institutional investors have recently made changes to their positions in LFST. Bayesian Capital Management LP purchased a new stake in LifeStance Health Group in the second quarter worth about $52,000. Cibc World Markets Corp purchased a new position in LifeStance Health Group during the 4th quarter valued at about $77,000. Qtron Investments LLC bought a new stake in shares of LifeStance Health Group in the 4th quarter valued at about $83,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of LifeStance Health Group by 569.1% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 12,024 shares of the company’s stock worth $85,000 after purchasing an additional 10,227 shares during the period. Finally, Orion Porfolio Solutions LLC bought a new position in shares of LifeStance Health Group during the fourth quarter valued at approximately $88,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.